Inhibition by human leukocyte elastase of neutrophil-mediated platelet activation

Eur J Pharmacol. 1993 Aug 2;248(2):151-5. doi: 10.1016/0926-6917(93)90037-q.

Abstract

When human polymorphonuclear neutrophils and platelets were incubated with human leukocyte elastase before N-formyl-Met-Leu-Phe (FMLP) challenge, a time- and concentration-dependent inhibition of the resulting platelet activation was observed. Thus, when the mixed cell suspension was preincubated for 6 min with 1 microM elastase before stimulation of neutrophils with 0.5 microM FMLP, resulting aggregations and serotonin releases were respectively only 4.4 +/- 4.1% (n = 4) and 1.6 +/- 2.4% (n = 4) as compared to 41.6 +/- 5.2% (n = 9) and 71.3 +/- 16.0 (n = 9) for controls. A direct inhibitory action of elastase on neutrophil activation was ruled out, as well as a breakdown of cathepsin G, a mediator involved in neutrophil-mediated platelet activation. In fact, we demonstrated that the target for the inhibitory effect of elastase in such a cell-to-cell cooperation system was the platelet. This phenomenon is likely to play a role under in vivo conditions in pathologies in which a significant granulocytic proteolytic activity has been detected in the plasma.

MeSH terms

  • Blood Platelets / drug effects*
  • Blood Platelets / metabolism
  • Cathepsin G
  • Cathepsins / metabolism
  • Dose-Response Relationship, Drug
  • Humans
  • Leukocyte Elastase
  • N-Formylmethionine Leucyl-Phenylalanine / pharmacology
  • Neutrophils / physiology*
  • Pancreatic Elastase / pharmacology*
  • Platelet Activation / drug effects*
  • Platelet Aggregation / drug effects
  • Serine Endopeptidases
  • Serotonin / metabolism

Substances

  • Serotonin
  • N-Formylmethionine Leucyl-Phenylalanine
  • Cathepsins
  • Serine Endopeptidases
  • CTSG protein, human
  • Cathepsin G
  • Pancreatic Elastase
  • Leukocyte Elastase